We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 11, 2020

Favorable Outcomes for High-Risk DLBCL Treated With Front-Line R-CODOX-M/R-IVAC Chemotherapy

Annals of Oncology


Additional Info

Annals of Oncology
Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated With Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial
Ann. Oncol 2020 May 25;[EPub Ahead of Print], AK McMillan, EH Phillips, AA Kirkwood, S Barrans, C Burton, S Rule, R Patmore, R Pettengell, KM Ardeshna, A Lawrie, S Montoto, S Paneesha, L Clifton-Hadley, DC Linch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading